334. Regional Anaesthesia (RA) as Value Driver in the Hospital - A Strategic Market Analysis

2008 ◽  
Vol 33 (Suppl 1) ◽  
pp. e27.1-e27
Author(s):  
A. R. Heller ◽  
O. Vicent ◽  
T. Koch
Keyword(s):  
Regional Anaesthesia ◽  
Market Analysis ◽  
Strategic Market

On-Line Analytical Processing at Washtenaw Mortgage

2011 ◽  
pp. 196-216
Author(s):  
John H. Heinrichs ◽  
William J. Doll
Keyword(s):  
Information Systems ◽  
Market Analysis ◽  
Ease Of Use ◽  
Executive Information Systems ◽  
Analysis Application ◽  
On Line ◽  
Stage Process ◽  
Analytical Processing ◽  
On Line Analytical Processing ◽  
Strategic Market

In an ever-changing, competitive marketplace, executive information systems (EIS) promise the ability to simultaneously assess factors in both the internal and external environment, enabling a timely competitive response. EIS are enjoying a renaissance due to the recent emergence of on-line analytical processing (OLAP) capabilities. OLAPs power, flexibility and ease of use supports mental model (knowledge) creation better than traditional executive information systems. This case study allows you to examine the usefulness and ease of use of OLAP technology for strategic market analysis at Washtenaw Mortgage Company, a firm in the mortgage wholesale industry. The key to improving competitive performance is not the technology, but rather, how the technology is utilized to focus managements analysis. Gaining strategic insights requires three ingredients people, process, and technology. A three-stage process used for implementing an OLAP strategic market analysis application is presented. OLAP technology marks an evolutionary improvement in EIS software. The potential of this technology, however, is not likely to be realized without a better understanding of the process for achieving management focus.

On-Line Analytical Processing at Washtenaw Mortgage Company

2011 ◽  
pp. 196-216
Author(s):  
John H. Heinrichs ◽  
William J. Doll
Keyword(s):  
Information Systems ◽  
Market Analysis ◽  
Ease Of Use ◽  
Executive Information Systems ◽  
Analysis Application ◽  
On Line ◽  
Stage Process ◽  
Analytical Processing ◽  
On Line Analytical Processing ◽  
Strategic Market

In an ever-changing, competitive marketplace, executive information systems (EIS) promise the ability to simultaneously assess factors in both the internal and external environment, enabling a timely competitive response. EIS is enjoying a renaissance due to the recent emergence of on-line analytical processing (OLAP) capabilities. OLAP’s power, flexibility and ease of use supports mental model (knowledge) creation better than traditional executive information systems. This case study allows you to examine the usefulness and ease of use of OLAP technology for strategic market analysis at “Washtenaw Mortgage Company”, a firm in the mortgage wholesale industry. The key to improving competitive performance is not the technology, but rather, how the technology is utilized to focus management’s analysis. Gaining strategic insights requires three ingredients – people, process, and technology. A three-stage process used for implementing an OLAP strategic market analysis application is presented. OLAP technology marks an evolutionary improvement in EIS software. The potential of this technology, however, is not likely to be realized without a better understanding of the process for achieving management focus.

Marketspace: Leading therapeutic recombinant protein sales forecast and analysis to 2010

2005 ◽  
Vol 12 (1) ◽  
Author(s):  
Mark J Belsey ◽  
Alex K Pavlou
Keyword(s):  
Growth Rate ◽  
Recombinant Protein ◽  
Market Analysis ◽  
Annual Growth Rate ◽  
Product Class ◽  
Lower Growth ◽  
Compound Annual Growth Rate ◽  
Sales Forecast ◽  
Strategic Market ◽  
Product Sales

As part of Datamonitor's biotechnology strategic market analysis, the authors have performed an analysis of the top 20 therapeutic recombinant proteins (defined by 2010 forecast sales), providing a forecast from 2004 to 2010 of product sales by therapeutic and product class. Based on this analysis, which was conducted in June 2005, leading companies operating in this sector are identified. Market analysis indicates that the total compound annual growth rate (CAGR) of these products from 2004 to 2010 is set to be 7.7 per cent, which is lower than other biotech markets such as the monoclonal antibody market. This lower growth rate reflects the mature nature of the therapeutic recombinant protein market. The arthritis, immune and inflammatory disorders franchise is set to record the strongest growth, with a forecast 2004–10 CAGR of 16.8 per cent, while the diabetes and endocrinology franchise is set to record the weakest growth (1.6 per cent). The leading product class in terms of total forecast 2010 sales is the erythropoietin class, which is set to generate approximately one-third of total top 20 product sales. The strongest-growing product classes are set to be fusion protein and colony-stimulating factors, while insulins are forecast to be the weakest-growing sector. Amgen is set to continue to lead the recombinant protein market over the forecast period, with the company's contribution to top 20 recombinant protein market sales set to rise from one-third of total 2004 sales to one-half of total 2010 sales.

A big data analytics based methodology for strategic decision making

2020 ◽  
Vol 33 (6) ◽  
pp. 1467-1490 ◽  
Author(s):  
Murat Özemre ◽  
Ozgur Kabadurmus
Keyword(s):  
Decision Making ◽  
Data Analytics ◽  
Big Data Analytics ◽  
Market Analysis ◽  
Strategic Decision ◽  
Strategic Decision Making ◽  
Strategic Decisions ◽  
Content Type ◽  
Strategic Market

PurposeThe purpose of this paper is to present a novel framework for strategic decision making using Big Data Analytics (BDA) methodology.Design/methodology/approachIn this study, two different machine learning algorithms, Random Forest (RF) and Artificial Neural Networks (ANN) are employed to forecast export volumes using an extensive amount of open trade data. The forecasted values are included in the Boston Consulting Group (BCG) Matrix to conduct strategic market analysis.FindingsThe proposed methodology is validated using a hypothetical case study of a Chinese company exporting refrigerators and freezers. The results show that the proposed methodology makes accurate trade forecasts and helps to conduct strategic market analysis effectively. Also, the RF performs better than the ANN in terms of forecast accuracy.Research limitations/implicationsThis study presents only one case study to test the proposed methodology. In future studies, the validity of the proposed method can be further generalized in different product groups and countries.Practical implicationsIn today’s highly competitive business environment, an effective strategic market analysis requires importers or exporters to make better predictions and strategic decisions. Using the proposed BDA based methodology, companies can effectively identify new business opportunities and adjust their strategic decisions accordingly.Originality/valueThis is the first study to present a holistic methodology for strategic market analysis using BDA. The proposed methodology accurately forecasts international trade volumes and facilitates the strategic decision-making process by providing future insights into global markets.

Autoimmune and inflammatory disorder biologicals will power biotech market growth through to 2010

2006 ◽  
Vol 12 (3) ◽  
Author(s):  
Clare A C Churchill ◽  
Mark J Belsey
Keyword(s):  
Market Analysis ◽  
Inflammatory Disorder ◽  
Annual Growth Rate ◽  
Market Growth ◽  
Compound Annual Growth Rate ◽  
Antibody Therapeutics ◽  
Wide Range ◽  
Will Power ◽  
Strategic Market ◽  
Biological Market

Biologicals designed to treat arthritis, immune and inflammatory disorders (AIID) are currently powering biotechnology market growth. Datamonitor's biotechnology strategic market analysis team has therefore analysed this market to identify key biological products, together with growth drivers and resistors shaping the growth of this market. The AIID market covers a wide range of indications; however, the most prevalent are rheumatoid arthritis and psoriasis, which together represent a significant healthcare burden. A range of monoclonal antibody therapeutics such as Abbott/CAT's Humira are set to drive AIID biological market growth, together with Amgen/Wyeth's fusion protein Enbrel. Owing to very strong sales of Enbrel as a result of continued label expansion, Amgen is set to record the greatest biological AIID sales from 2004 to 2010. Many of the highly efficacious AIID biologicals such as Enbrel target TNF, which is rapidly emerging as the leading cytokine target for many AIID indications. Overall, AIID biologicals generated US$5.4bn in 2004, and this is set to rise to US$14.3bn by 2010: a strong compound annual growth rate of 17.9 per cent.

Sign in / Sign up

Export Citation Format

Share Document